Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Surgery Partners (SGRY) EBITDA Margin: 2014-2025

Historic EBITDA Margin for Surgery Partners (SGRY) over the last 12 years, with Q3 2025 value amounting to 12.87%.

  • Surgery Partners' EBITDA Margin rose 49600.0% to 12.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.36%, marking a year-over-year increase of 15400.0%. This contributed to the annual value of 15.85% for FY2024, which is 2200.0% down from last year.
  • Surgery Partners' EBITDA Margin amounted to 12.87% in Q3 2025, which was up 49600.0% from 13.52% recorded in Q2 2025.
  • In the past 5 years, Surgery Partners' EBITDA Margin ranged from a high of 18.81% in Q4 2021 and a low of 6.96% during Q1 2023
  • For the 5-year period, Surgery Partners' EBITDA Margin averaged around 12.34%, with its median value being 12.43% (2022).
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 76400bps in 2021, then plummeted by -98800bps in 2023.
  • Surgery Partners' EBITDA Margin (Quarter) stood at 18.81% in 2021, then decreased by -29bps to 13.32% in 2022, then rose by 4bps to 13.79% in 2023, then increased by 7bps to 14.7% in 2024, then decreased by -12bps to 12.87% in 2025.
  • Its last three reported values are 12.87% in Q3 2025, 13.52% for Q2 2025, and 7.98% during Q1 2025.